Fig. 3: ASAH1 inhibitor carmofur inhibits TNBC growth and metastasis in vitro. | Cell Death & Disease

Fig. 3: ASAH1 inhibitor carmofur inhibits TNBC growth and metastasis in vitro.

From: ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability

Fig. 3

A The indicated TNBC cancer cell lines were treated with different concentrations of ASAH1 inhibitor carmofur for 3 days, and survival was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell survival in carmofur treatment condition is plotted relative to the control DMSO treatment. B The indicated TNBC cell lines were treated with different concentrations of carmofur and analyzed for their abilities to grow in soft-agar assay. Representative images are shown (left) with a scale bar of 500 µm. Relative colony sizes for the images are shown (right). C The indicated TNBC cell lines were treated with different concentrations of carmofur for 2–4 weeks. Cell survival was measured using clonogenic assay. Representative images are shown. D The indicated TNBC cell lines were treated with different concentrations of carmofur and analyzed for their invasive ability using Matrigel-based invasion assays. Representative images are shown at a scale bar of 200 µm. E Quantitation of the data presented in (D). F Migration was analyzed in a wound-healing assay for TNBC cancer cell lines treated with different concentrations of carmofur or control DMSO. Representative images are shown at a scale bar of 200 µm. G Quantitation of the data presented in (F). Data represent the mean ± standard error for three biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant.

Back to article page